<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sandin D</submitter><funding>Spanish Ministerio de Ciencia e Innovación</funding><funding>Ministerio de Ciencia e Innovación</funding><funding>La Caixa Banking Foundation</funding><funding>European Society of Clinical Microbiology and Infectious Diseases</funding><funding>European Union Next GenerationEU/ PRTR to M.T.;</funding><funding>Spanish Ministry of Economy and Innovation</funding><pagination>2169</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9611985</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(10)</volume><pubmed_abstract>Antimicrobial peptides (AMPs) are widely distributed molecules secreted mostly by cells of the innate immune system to prevent bacterial proliferation at the site of infection. As with classic antibiotics, continued treatment with AMPs can create resistance in bacteria. However, whether AMPs can generate tolerance as an intermediate stage towards resistance is not known. Here, we show that the treatment of &lt;i>Escherichia coli&lt;/i> with different AMPs induces tolerance by lag, particularly for those peptides that have internal targets. This tolerance can be detected as different morphological and physiological changes, which depend on the type of peptide molecule the bacterium has been exposed to. In addition, we show that AMP tolerance can also affect antibiotic treatment. The genomic seque</pubmed_abstract><journal>Pharmaceutics</journal><pubmed_title>Antimicrobial Peptides Can Generate Tolerance by Lag and Interfere with Antimicrobial Therapy.</pubmed_title><pmcid>PMC9611985</pmcid><funding_grant_id>ESCMID2022</funding_grant_id><funding_grant_id>PID2020-114627RB-I00; PDC2021-121544-I00</funding_grant_id><funding_grant_id>HR17-00409</funding_grant_id><funding_grant_id>PID2020-114627RB-I00</funding_grant_id><funding_grant_id>PDC2021-121544-I00</funding_grant_id><pubmed_authors>Torrent M</pubmed_authors><pubmed_authors>Valle J</pubmed_authors><pubmed_authors>Sandin D</pubmed_authors><pubmed_authors>Morata J</pubmed_authors><pubmed_authors>Andreu D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Antimicrobial Peptides Can Generate Tolerance by Lag and Interfere with Antimicrobial Therapy.</name><description>Antimicrobial peptides (AMPs) are widely distributed molecules secreted mostly by cells of the innate immune system to prevent bacterial proliferation at the site of infection. As with classic antibiotics, continued treatment with AMPs can create resistance in bacteria. However, whether AMPs can generate tolerance as an intermediate stage towards resistance is not known. Here, we show that the treatment of &lt;i>Escherichia coli&lt;/i> with different AMPs induces tolerance by lag, particularly for those peptides that have internal targets. This tolerance can be detected as different morphological and physiological changes, which depend on the type of peptide molecule the bacterium has been exposed to. In addition, we show that AMP tolerance can also affect antibiotic treatment. The genomic seque</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2026-04-08T18:20:37.434Z</modification><creation>2025-04-19T04:23:33.84Z</creation></dates><accession>S-EPMC9611985</accession><cross_references><pubmed>36297604</pubmed><doi>10.3390/pharmaceutics14102169</doi></cross_references></HashMap>